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AbstrACt
Introduction The proximal humerus fracture (PHF) is one 
of the most common fractures in the elderly. The majority 
of PHFs are treated non-operatively, while 15%–33% of 
patients undergo surgical treatment. Recent randomised 
controlled trial (RCT) and meta-analyses have shown that 
there is no difference in outcome between non-operative 
treatment and locking plate or hemi-arthroplasty. During 
the past decade, reverse total shoulder arthroplasty (RTSA) 
has gained popularity in the treatment of PHF, although 
there is a lack of RCTs comparing RTSA to non-operative 
treatment.
Methods This is a prospective, single-blinded, 
randomised, controlled, multicentre and multinational trial 
comparing RTSA with non-operative treatment in displaced 
proximal humeral fractures in patients 65–85 years. 
The primary outcome in this study is QuickDASH-score 
measured at 2 years. Secondary outcomes include visual 
analogue scale for pain, grip strength, Oxford shoulder 
score, Constant score and the number of reoperations and 
complications. The hypothesis of the trial is that operative 
treatment with RTSA produces better outcome after 2 and 
5 years measured with QuickDASH.
Ethics and dissemination In this protocol, we describe 
the design, method and management of the Nordic 
DeltaCon trial. The ethical approval for the trial has 
been given by the Regional Committee for Medical and 
Health Research Ethics, Norway. There have been several 
examples in orthopaedics of innovations that result in 
failure after medium-term follow-ups . In order to prevent 
such failures and to increase our knowledge of RSTA, 
we feel a large-scale study of the effects of the surgery 
on the outcome that focuses on the complications and 
reoperations is warranted. After the trial 2-year follow-up, 
the results will be disseminated in a major orthopaedic 
publication.
trial registration number NCT03531463; Pre-Results.
IntroduCtIon 
In the ageing population, the proximal 
humerus fracture (PHF) is one of the most 
common fractures. In addition to the signif-
icant disability caused by PHF among older 
individuals, such fractures are also asso-
ciated with a high economic impact.1 2 In 
general, the operative interventions and 
rehabilitation after a shoulder fracture are 
resource consuming. Furthermore, it has 
been suggested that a significant proportion 
strengths and limitations of this study
 ► The publication presents the efficacy randomised 
controlled trial (RCT) on proximal humerus fracture.
 ► The trial fills an urgently needed knowledge gap in 
a rapidly increasing method used in proximal hu-
merus fracture comparing reversed prosthesis with 
non-operative treatment.
 ► In order to improve generalisability of results, the 
trial will be conducted in several trauma centres in 
Nordic countries with similar healthcare system.
 ► The strength of our study setting is the experience of 
the researchers and personnel gained from previous 
large RCTs.
 ► The limitation is the normal issue of external validity.
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of common medical interventions— including ortho-
paedics—are not based on solid high-quality scientific 
evidence.3 Despite this, many of them are still widely 
used.4 5 There have been alarming reports showing that 
operative treatment of some common fractures, such as 
distal radius and proximal humerus, is increasing without 
any evidence to support the operative treatment of these 
fractures.4 5 
The sex-specific fracture incidence for proximal 
humeral fractures for women in Sweden was 135 per 
100 000 person-years6; in total, almost 10 000 fractures 
were diagnosed in 2012.6 The majority of PHFs are treated 
non-operatively and approximately 15%–33% of patients 
are treated surgically.7 Recent randomised controlled 
trials (RCTs) and meta-analyses have shown that there is 
no difference in functional outcome between non-oper-
ative treatment and locking plate or hemi-arthroplasty 
(HA) in the treatment of PHF. However, operative treat-
ment has a significantly higher risk of complications and 
reoperations of up to 30%.8–11
Originally, reverse total shoulder arthroplasty (RTSA) 
was used in osteoarthrosis in patients without cuff func-
tion to gain better functional outcomes. During the past 
decade, however, RTSA has gained popularity in the 
treatment of PHF. In a recent Medicare population anal-
ysis carried out between 2005 and 2012, the proportion 
of surgical procedures for PHF that were total shoulder 
arthroplasties (TSA) (of which RTSAs constituted 89% in 
2011) increased from 3% to 17%, while the proportion 
of HA decreased from 42% to 24% during the same time 
period.7 12 There have been some systematic reviews based 
on case series and patient cohorts including one RCT 
that compared HA and RTSA. The results are equivocal, 
RTSA resulted in better functional outcomes compared 
with HA in some studies,13 14 with no difference seen in 
others.15 In the RCT, the complication rate in the HA 
group was significantly higher than in the RTSA group 
(24% vs 10%, respectively).16 However, an arthroplasty 
registry analysis including 10 844 operations (6658 TSA 
and 4186 RTSA) showed the RTSA postoperative compli-
cation rate to be 22% at 2 years.17 The results from a cost 
analysis concluded that RTSA treatment is significantly 
more expensive than HA treatment ($57 000 vs $33 480, 
respectively).18
Currently, there are no RCTs comparing RTSA to 
locking plate or non-operative treatment after PHF. The 
current literature seems to discourage the operative 
treatment of PHF with locking plate or HA, and there 
is no evidence that favours surgery over non-operative 
treatment.9 11 In spite of the substantial costs and lack of 
evidence supporting the effectiveness of RTSA for PHF, it 
has become the accepted standard of care in the USA.19 
Therefore, there is an urgent need for high-quality RCTs 
that compare RTSA with non-operative treatment.
The Nordic Innovative Trials to Evaluate osteoporotic 
fractures—NITEP collaboration began with a trial of 
proximal humerus fractures (R10127, NCT01246167). 
The aim of the present trial is to compare RTSA and 
non-operative treatment in the treatment of proximal 
humerus fracture in the elderly. When conducting a 
randomised controlled multicentre trial, the critical 
points are the patient recruitment rate and the stability 
of key personnel. Therefore, a multicentre Nordic collab-
oration is warranted. In our previous RCT, our collabo-
ration was found to be both reliable and effective in the 
recruitment of patients. Furthermore, we are confident 
that the planned Nordic DeltaCon trial is feasible and 
that it will have an impact on the daily management of 
these difficult and controversial fractures.
MEthods And AnAlysIs
This is a prospective, superiority, single-blinded, 
randomised, controlled, multicentre and multinational 
trial that will compare RTSA and non-operative treatment 
in proximal humerus fractures in patients aged 65–85 
years with displaced three-part and four-part fractures (B 
and C types) according to the recent AO/OTA 2018 revi-
sion.20 The trial setting has been drafted in accordance 
with the Consolidated Standards of Reporting Trials 
(CONSORT) and Standard Protocol Items: Recommen-
dations for Interventional Trials (SPIRIT) statements.
The hypothesis of the trial is that RTSA produces a 
better functional outcome and less pain compared with 
non-operative treatment at 2 years.
The primary outcome in this study will be the Quick-
DASH (the short form of Disabilities of the arm, shoulder 
and hand) score measured at 2 years. Secondary outcomes 
will be the QuickDASH score after 1, 2 (short term) and 
5 years (medium term), general visual analogue scale 
(VAS) for pain, grip strength, the Oxford shoulder score 
(OSS), the Constant score (CS) and the number of reop-
erations and complications. Quality of life will be assessed 
with 15-D. Cost-effectiveness analysis will be performed 
after completion of the trial. The questionnaires used in 
the trial will be repeated after 10 years with those patients 
who are still reachable. During all time points, the compli-
cations and reoperations will be recorded.
Patient selection
The eligible study population will comprise all consecu-
tive patients aged 65–85 years with a proximal humerus 
fracture diagnosed within 7 days and operated within 14 
days of the trauma. The upper age limit was chosen to 
limit loss to follow-up due to unrelated cause mortality 
and to exclude those patients with a very high surgical 
risk. The lower age limit was chosen according to a recent 
publication by Sebastian-Forcada et al.16 They found that 
RTSA had better outcomes in patients >70 years of age 
compared with HA. Additionally, the complication rate 
with RTSA was found to be lower than for HA, and thus 
we decide that it would be safe to set the lower age limit 
at 65 years. In another RTSA trial that included patients 
aged 65 years or over,21 the number of adverse events 
(AEs) after interim analysis was less than reported in the 
literature, which also supports the lower age limit.
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The research nurse will be notified of any patients 
screened for the trial who decline to take part or are 
excluded from the randomisation. The nurse will then 
complete a patient information form in order to collect 
the total number of patients screened.16 Patients who 
decline from taking part in the trial will be asked to join 
the follow-up cohort allowing us to evaluate external 
validity.
The following criteria will be used throughout the study 
for patient selection.
Inclusion criteria:
 ► Low-energy AO/OTA group 11-B1.1, 11-B1.2 and 
11-C1.1, 11-C3.1. Both B and C type includes the 
subgroups: displaced,2 impacted3 or non-impacted4 
from the universal modifiers list.
Exclusion criteria:
Radiographic
 ► Mal-inclination less than varus 30°or valgus 45°.
 ► Less than 50% contact between head fragment and 
metaphysis/diaphysis.
 ► Head split fractures (group 11-C3.2 and 11-C3.3) 
with >10% of the articular surface in the main head 
fragment.
 ► Dislocation or fracture dislocation of the gleno-hu-
meral joint.
 ► Pathological fracture.
 ► Glenoid abnormality (retroversion, >15°; glenoid 
fracture; cuff arthropathy).
General
 ► Refuses to participate in the study.
 ► Aged <65 years or >85 years.
 ► Serious poly-trauma or additional surgery.
 ► Non-independent, drug/alcohol abuse or institution-
alised (low co-operation).
 ► Contraindications for surgery (severe cardiovascular, 
pulmonal or neurological comorbidity).
 ► Does not understand written and spoken guidance in 
local languages.
 ► Previous fracture with symptomatic sequelae in either 
shoulder.
 ► Patients living outside the hospital’s catchment area.
randomisation
Patients will be randomised using a random number 
matrix in block allocation fashion. The blocks will be 
stratified by age (65–75 years and >75 years) since age has 
been shown to associate with the main outcome measure. 
The treatment allocations from the matrix will be 
acquired from an online randomisation system (website 
http:// randomize. net), where the researcher logs in 
after written consent and receives the correct interven-
tion. The physician responsible for the intervention or 
treatment will not participate in any part of the collection 
of patient outcomes during the follow-ups. The research 
coordinator will monitor the study flow. An independent 
monitoring committee has been established with our 
previous RCT.
surgical treatment
Operative treatment will be performed as a daytime 
procedure by trained and experienced upper extremity 
surgeons. The surgeons’ skills and number of proce-
dures from each centre will be reported according to the 
criteria given by the Consort Group.22
The aim of surgical treatment is to restore proper 
biomechanics, to achieve an optimal range of motion 
and to minimise patient discomfort. The standardised 
approach will be the delto-pectoral to minimise any 
damage to the deltoid muscle. Supraspinatus excision 
and biceps tenotomy will be performed. A cemented 
monoblock humeral stem will then be implanted, in a 
neutral version. An important point that will be addressed 
is to ensure proper tension and stability of the prosthesis. 
Fixation of the greater and lesser tubercles is important 
in optimising the ability and strength of internal and 
external rotation.23 When necessary, braided polyester 
suture–cerclages engaging the insertion of the subscap-
ular and infraspinatus tendons enforced by a bone graft 
or a ‘horseshoe-graft’24 from the humeral head will be 
used. If the surgical neck fracture extends further distal 
than the humerus metaphysis, a diaphyseal cerclage 
will be applied to prevent further diaphyseal fracturing. 
Finally, to reduce the risk of the radiographic ‘scapular 
notching’, the largest glenosphere will be used to secure 
an inferior prosthetic overhang with reference to the 
scapular neck and to reduce the risk of any instability of 
the prosthesis.25
non-operative treatment
Patients in the non-operative group will be immobil-
ised in a sling for 2 weeks before starting self-exercises 
and instructed physiotherapy. Postoperative treatment 
differs with respect to timeline between the surgical 
treatment group and the non-operative group due to the 
different degree of stability for a reversed prosthesis and a 
non-operatively treated displaced fracture (table 1). The 
elements of physiotherapy will, however, be the same.21 26
rehabilitation
In order to achieve as good functional outcomes as 
possible, the rehabilitation protocols will be standardised 
in both treatment groups and the patients will be given a 
written protocol. Patients in both groups will be guided by 
in-ward physiotherapists and will be given written physio-
therapy guidelines for both instructed physiotherapy and 
self-exercises. After discharge from the hospital, patients 
will be referred to physiotherapy for further guidance. 
Patients in the operative group will start exercises from 
the first postoperative day to reduce haematoma in the 
‘dead space’ created by resection of the supraspinatus 
tendon and the design of the reverse prosthesis. For a 
detailed rehabilitation programme, please see table 1.
Follow-up
Patients will visit the orthopaedic outpatient clinic at 
the hospital for a follow-up visit with the orthopaedic 
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surgeons at 3 months. We recommend a 2 weeks follow-up 
for the non-operative group to confirm the rehabili-
tation program can start: An additional radiographic 
examination to exclude secondary facture displacement, 
and instruction by a physiotherapist after removal of 
the sling. Research visits will take place at 1, 2, 5 and 10 
years. During these visits, the QuickDASH, OSS, CS, 15D 
and plain X-rays examinations will be performed. At the 
research visit, the patients will be asked to wear a shirt and 
instructed not to provide information about their treat-
ment group to ensure the researcher or physiotherapist 
are blind to the initial treatment.
Should any AE occur at any point during the follow-up, 
an AE report will be sent to the Tampere research nurse. 
Patients initially allocated to the non-operative group but 
later operated on during the trial will be analysed based 
on the intention-to-treat principle.
At 1-year control in selected sites, patients will be asked 
for their consent to take part in an additional study. 
Should patients agree to take part they will have acceler-
ometer censors attached by plasters to both upper arms 
for a week. The sensors will measure 24/7 activity and 
degree of movement. With these data, we will be able 
to compare the activity levels of both treatment groups 
Table 2 Assessments and procedures of the trial
Assessment Preoperative
2. Visit
3 months
3. Visit
1 year
4. Visit
2 year
5. Visit
5 years
6. Visit
10 years
X-ray X X X X X X
CT X X
Exclusion/inclusion X
Medical history X
Consent X
Questionnaire X X X X X X
Self-assessment X X X
VAS pain X X X X X X
QuickDASH X X X X X
15D X X X X X
OSS X X X X X
CS score X X X X
Physician visit X X X X X X
Research visit X X X X
Grip strength X X X X X X
CS, Constant score; OSS, Oxford shoulder score; VAS, visual analogue scale.
Table 1 The rehabilitation guidelines
Elements of physical therapy
Group 1
Reversed prosthesis
Group 2
Non-operative treatment
Antioedema elbow, hand and fingers. Day 1 Day 1
Positioning of the scapula. Day 1 Day 1
Pendulum exercises. Passive and active assisted exercises in 
flexion, abduction and rotation.
Day 1* 2 weeks
Active exercises. Functional exercises. Isometric resistance with the 
shoulder in neutral position.
6 weeks 6 weeks
Active dynamic strengthening exercises. 8 weeks 8 weeks
Stretching exercises to progressively increase ROM in all positions. No 10 weeks
Progress strengthening exercises, weightbearing exercises through 
the upper extremity to improve shoulder proprioception.
12 weeks 12 weeks
All weeks mean after treatment start in weeks.
*Gradually increasing mobility, external rotation to neutral position in the first six weeks after surgery.
ASA, American society of Anesthesiologists - Physical status classification system; ROM, range of motion.
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at 1 year after the fracture treatment and to compare 
the acquired data with the patients’ healthy side. A full 
list of trial assessments and procedures is presented in 
table 2.
Patients who decline to attend the intervention trial will 
be asked to join the external follow-up group. This group 
will be used as external validation; the group content and 
outcomes will be compared with the allocated interven-
tion and control groups. The treatment will be carried 
out in line with normal clinical practice, but the patients 
will have the same follow-up and be asked to fill out the 
same questionnaires as the allocated patients.
Complications
Complications will be categorised as follows:
 ► Infection.
The definition of infections is the following:
a. Less serious infection: Superficial wound infection 
with sign of skin inflammation and/or a positive bacte-
rial culture, without call for resurgery.27
b. Deep infection: Any postoperative wound infection or 
sign of deep infection that calls for resurgery with pos-
itive perioperative bacterial cultures or as defined after 
in consensus criteria for periprosthetic joint infection 
(musculoskeletal infection society).
 ► Non-union.
 ► Implant failure, including dislocation.
 ► Painful capsulitis after 6 months.
 ► Nerve damage.
 ► Complex regional pain syndrome.
Power analysis
Assuming the effect size of a 14-point difference in the 
QuickDASH score and an SD of 26.8 points (from previous 
Olerud and MacDermid trials), the estimated sample 
size will be 59 patients per group (delta=14, SD=26.8, 
alpha=0.05, power=0.8).28–30 With this age group, the esti-
mate of loss in follow-up rate will be set to 30% and results 
in a total of 154 patients in the trial.31
statistical analysis
The differences between groups in main outcome vari-
ables will be analysed by t-test when variables are unskewed, 
and by the Mann-Whitney U test if continuous skewed. 
Results will be presented with 95% CIs. Two-way tables 
with the χ2 test will be used for dichotomous variables. In 
subgroup analysis, the effect of age, sex, fracture group, 
smoking, ASA class and premorbidity will be evaluated 
against the scores and overall quality of life after fracture.
The effect of the treatment using the QuickDASH will 
be investigated in the multivariate manner. Multivariable 
analysis will be performed with linear regression anal-
ysis since the outcome variable QuickDASH is normally 
distributed due to adequately sized groups. The main 
variable of interest included will be the intervention, and 
age, sex, fracture group, smoking and premorbidity will 
be used as confounding variables.
data management plan
Each patient will be assigned a unique trial identification 
number (TIN), which is matched with the patient’s identi-
fication. The matching key will be stored in a locked parti-
tion on the hospital research server at Tampere University 
Hospital, Finland, and will only be available to two study 
nurses. The identification of each patient will only be 
possible after retrieving the matching key. Throughout 
the trial, the research data will only be handled with a 
TIN. The research data will be saved to a database with a 
NITEP tailored online patient management programme 
(Berta) located on a secure research server provided by 
Tampere University Hospital and approved by the Secu-
rity Committee of Tampere University Hospital. Only 
users with a registered account will be able to log in to 
the system and registered accounts will be provided by 
the administrator. The research data saved to the server 
will contain only anonymous TINs with a set of numbers 
acquired from the questionnaires; that is, each question is 
answered with a number. This will ensure the anonymity 
of each individual patient, and that the identity of the 
patient will remain secret, even if the server data are 
revealed to third parties.
All primary and secondary data will be acquired and 
stored on the study trial server. Data will be entered either 
by the patient during the control visits (via tablets) or by 
a researcher or research nurse when the questionnaires 
are returned by post. The researchers from each hospital 
will have access to the secure study server where the trial 
research data are stored. Each researcher will gain access 
to the data at the end of the trial for further analyses. All 
variables in the data set will be described, and suitable 
metadata standards will be used, when available.
The copyright of the trial research data will be owned 
and created by the collaboration parties. The data will be 
shared freely among collaboration parties, and all partic-
ipating researchers will receive access after the trial is 
completed. Due to confidentiality and legal agreements, 
public data sharing will be restricted because we only 
have permission to hold the data in the specific research 
server, not to transfer data. Under certain circumstances, 
for example, when a new member joins the collaboration, 
we will grant access to the data. All data will be saved for 
15 years after the end of the trial.
Patient and public involvement in trial
In order to improve patient involvement in the trial, we 
will interview patients with proximal humerus fracture 
before the onset of the trial. The aim of the interviews will 
be to move towards patient-centred medicine by taking 
into account the goals, preferences and values of patients. 
We will further involve patients by asking questions at the 
beginning of the treatment (self-assessment) in order to 
identify the questions to ask and the outcomes to measure. 
The interviews will be repeated after 1 and 2 years, and the 
results (difference or indifference between the primary 
and follow-up responses) will be reported.
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Interim analysis
The external trial board will execute the interim anal-
ysis after half of the patients have been recruited. The 
report will be focused on the number of AEs and will give 
a recommendation as to whether or not the trial should 
continue. AEs and serious adverse events (SAEs) will be 
reported according to the recommendations given by the 
Consort Group.
AE is defined as follows:
1. For the RTSA intervention group, the primary focus 
will be postoperative deep infections27 requiring revi-
sion surgery, instability, periprosthetic fracture, radio-
graphic early signs of loosening (within 2 years of the 
surgery) of the humeral stem or notching of the scap-
ula neck.
2. For the non-operative group, the primary focus will 
be on the rate of secondary surgery for any reason 
(eg, non-union, symptomatic avascular head necrosis, 
osteoarthrosis).
Both groups will be monitored for SAE during the 
first four weeks after discharge for embolism (cardiac or 
brain) or death. The research nurse will fill out AE and 
SAE forms at 3 months control, if needed.
At the halfway point of the trial (50% of patients 
recruited), an independent steering committee will eval-
uate the complication rates and correlate them to the 
expected rates published in the available literature.
An unexpected high rate of complications in either 
group will be reported to the project group, who will then 
decide whether to end the randomisation.
Contingency plan
All participating hospitals have a significant volume of 
trauma patients, and they provide continuous emergency 
care and trauma surgery. In addition, all collaboration 
sites are academic teaching hospitals that are familiar 
with good clinical research practices. Proximal humerus 
fractures are common in these hospitals, and thus the 
infrastructure of the hospitals is highly standardised. 
For example, all participating hospitals have upper-ex-
tremity treatment units. Moreover, all hospitals have the 
appropriate equipment available, such as an operating 
environment and facilities for postoperative hospitalisa-
tion. All participating institutes have agreed to provide 
all the equipment and facilities necessary to conduct the 
trial. Local science centres will provide support in main-
taining Good Clinical Practice principles, in assisting in 
the administration and invoicing for the trials, and in 
executing trial monitoring.
recruitment policy
The centres will be encouraged to recruit as many patients 
as possible. However, if one centre is unable to continu-
ously recruit enough patients annually, it would be imprac-
ticable to include the centres findings in the statistical 
model, and therefore the centre would be excluded from 
the trail. The minimum number of patients recruited per 
year will be five.
trIAl sChEdulE
The initial piloting of the trial will begin in Norway in early 
October 2018 all-together with six sites. The other collab-
orators will join after the trial protocol has been shown 
to be working flawlessly. During 2019, all sites will begin 
recruiting, and we estimate that the inclusion process will 
be completed with full groups after 2 years (end of 2020). 
Analysis and results of the trial will be published (dissem-
inated) during 2022.
EthICs And dIssEMInAtIon
The ethical approval for the trial has been given by the 
Regional Committee for Medical and Health Research 
Ethics, South-East Authority, Norway (2018/476 REK 
sør-øst D, https:// helseforskning. etikkom. no/. All 
patients included in the trial and those who declined but 
were asked to take part in ordinary follow-up will be asked 
to give written informed consent. All patient data will be 
handled in an anonymous fashion and the results will be 
published at the group level only, and individual patients 
will not be identifiable.
In this protocol, we describe the set-up and manage-
ment of the Nordic Deltacon trial. The efforts to develop 
new operative techniques during the past years seem to 
have resulted in no improvement for patients suffering 
from PHF. With all the excitement around the newest 
technique, RTSA, we feel there is an urgent need for a 
large-scale study of the effects of the technique on the 
outcome, with special attention on complications and 
reoperations. This will assure the safe and ethical usage 
of RTSA in the future.
The absolute strength of the study will be the experi-
ence of the study group in handling a large-scale RCT. 
In this kind of efficacy study, the paramount aspect is 
the uniformity of the patient handling, and it may be 
the limitation of the study if not taken care of properly. 
However, with our previous experiences, we have learnt 
to overcome these pitfalls by regular biannual meetings 
among the researchers, personnel education sessions and 
written aftercare and follow-up protocols. Third-party 
monitoring is essential for checking the trial manage-
ment and for notifying of any missing parts in the data 
handling. External validity is always a matter of debate 
in RCTs. Good documentation, pre-trial workshops and 
continuous discussion among the team will clarify the 
patients recruited to the trial.
The previous data show moderate to good outcomes 
with non-operative treatment for patients with PHF in 
cases where the fracture parts are in continuity with the 
stem. And therefore, the usage of RTSA should be limited 
to only the most severe and displaced cases of PHF until 
the primary results of this trial are available.
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